Sarah Hamidi, M.D., FRCPC
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
Present Title & Affiliation
Primary Appointment
Associate Patient Safety Quality Officer, Endocrine Neoplasia and HD, Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Assistant Professor, Endocrine Neoplasia and Hormonal Disorders, Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Dual/Joint/Adjunct Appointment
Assistant Professor, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2017 | University of Montreal, Montreal, QC, CA, Medicinae Doctorem (M.D.) |
| 2013 | University of Montreal, Montreal, QC, CA, Pre-medical Year |
Postgraduate Training
| 2022-2024 | Advanced clinical and research fellowship, Oncologic Endocrinology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2021-2022 | Chief Resident, Adult Endocrinology and Metabolism, The University of Montreal Hospital Center (CHUM), Montreal, QC |
| 2020-2022 | Clinical fellowship, Adult Endocrinology and Metabolism, University of Montreal, Montreal, QC |
| 2017-2020 | Clinical residency, Internal Medicine, University of Montreal, Montreal, QC |
Licenses & Certifications
| 2025 | Texas Medical License |
| 2022 | Board Certification in Adult Endocrinology and Metabolism by the Royal College of Physicians and Surgeons of Canada |
| 2020 | Board Certification in Internal Medicine by the Royal College of Physicians and Surgeons of Canada |
Experience & Service
Other Professional Positions
Clinical Research Scientist, Endocrinology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - 2025
Intramural Institutional Committee Activities
Co-chair, ALTER ATC: Adaptive Learning to improve Thyroid Cancer Responses in Anaplastic Thyroid Cancer, The University of Texas MD Anderson Cancer Center, 2024 - Present
Member, ACTION QI: Advanced Cancers of the Thyroid early Interrogation for Oncologic and Neoadjuvant Targets, The University of Texas MD Anderson Cancer Center, 2023 - 2025
Co-leader, Safety Monitoring for Patients with Advanced Thyroid Cancer on Targeted Therapy, The University of Texas MD Anderson Cancer Center, 2022 - 2025
Extramural Institutional Committee Activities
Member, Anaplastic Thyroid Cancer Taskforce, International Thyroid Oncology Group, 2025 - Present
Member, Redifferentiation Therapy Thyroid Cancer Taskforce, International Thyroid Oncology Group, 2025 - Present
Co-chair, Continuing Professional Development Committee of the Division of Endocrinology and Metabolism, The University of Montreal Hospital Center (CHUM), 2021 - 2022
Member, Trainee representative, Continuing Professional Development Committee of Quebec's Association of Endocrinologists, Quebec's Association of Endocrinologists, 2021 - 2022
Member, Adult Endocrinology and Metabolism Fellowship Program Admissions Committee, University of Montreal, 2021
Member, Well-being Committee of the Division of Endocrinology and Metabolism, The University of Montreal Hospital Center, 2020 - 2022
Honors & Awards
| 2025 | Travel Grant for the 2025 International Thyroid Congress, American Thyroid Association |
| 2025 | Cyrus Scholar Award for Outstanding Clinical Research, The University of Texas MD Anderson Cancer Center |
| 2024 | 2024 Outstanding Trainee Poster Award, American Thyroid Association |
| 2024 | Ridgeway Trainee Travel Grant, American Thyroid Association |
| 2023 | 2023 Women Advancing Thyroid Research Award, American Thyroid Association |
| 2023 | Ridgeway Trainee Travel Grant, American Thyroid Association |
| 2023 | First place at the 2023 Division of Internal Medicine Research Retreat, Clinical Research poster session, The University of Texas MD Anderson Cancer Center |
| 2022 | Dean's Honor List - Postgraduate Medical Education, University of Montreal |
| 2022 | The Department of Medicine's Trainee Excellence Award, The University of Montreal Hospital Center (CHUM) |
| 2018 | Internal Medicine Resident Excellence Award, Maisonneuve-Rosemont Hospital, Montreal, QC |
| 2017 | Dean's Honor List - M.D, University of Montreal |
| 2012 | Highest Honors and Jury's Praise at the French Baccalaureate, Stanislas College, Montreal, QC |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Cabanillas ME, Busaidy NL, Zafereo M, Iyer PC, Wang JR, Hamidi S, Ferrarotto R, Liu S, Gunn GB, Spiotto M, Lee A, Maniakas A, Gule-Monroe M, Williams MD, Hosseini SM, Banuchi VE, Hu MI, Ning M, Dadu R. Lenvatinib plus pembrolizumab for the treatment of patients with non-BRAF mutated anaplastic thyroid cancer: A single center, phase 2 clinical trial. Eur J Cancer 246:117013, 2026. e-Pub 2026. PMID: 42673705.
- Marczyk VR, Li S, Wu CC, Loberg MA, Henderson Y, Martin M, Hamidi S, Waguespack S, Busaidy N, Dadu R, Iyer P, Hu M, Banuchi V, Maniakas A, Lai S, Zafereo M, Williams MD, Hosseini SM, Sheng Q, Xu GJ, Huang EC, Weiss VL, Cabanillas M, Wang JR. TERT Promoter Variants, Older Age, and Prognosis in Papillary Thyroid Carcinoma. JAMA Otolaryngol Head Neck Surg, 2026. e-Pub 2026.
- Hamidi S, Dadu R. A step forward for precision oncology in thyroid cancer. Lancet Oncol 27(8):911-913, 2026. e-Pub 2026. PMID: 42442382.
- Marczyk VR, Wu CC, Hamidi S, Li S, Loberg MA, Martin M, Williams MD, Hosseini SM, Waguespack S, Hu M, Sherman SI, Henderson Y, Lai S, Dai Y, Wang W, Maniakas A, Zafereo M, Sheng Q, Xu GJ, Huang EC, Weiss VL, Cabanillas M, Wang JR. Revised Thyroid Differentiation Score for Risk Stratification in Papillary Thyroid Carcinoma. JCO Precis Oncol 10(7):e2600207, 2026. e-Pub 2026. PMID: 42492028.
- Salim, H, Learned, KO, Zafereo, M, Wang, RJ, Msherghi, A, Dagher, SA, Taslicay, CA, Al Qudah, H, Alizada, S, Hu, MI, Cabanillas, ME, Busaidy, NL, Hamidi, S, Tawbi, H, Eldaya, R, Li, J, Wintermark, M. Whole-Brain Radiation Therapy for Brain Metastases due to Thyroid Cancer. Clinical Oncology 52, 2026. e-Pub 2026. PMID: 41780125.
- Hamidi S, Vodopivec DM, Busaidy NL, Gule-Monroe M, Akhave NS, Banuchi VE, Ferraroto R, Fournier I, Gunn GB, Iyer PC, Lee A, Maniakas A, Marczyk VR, Ning MS, Sousa LG, Spiotto MT, Waguespack SG, Wang JR, Zafereo ME, Cabanillas ME, Dadu R. Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma. Thyroid 36(2):153-161, 2026. e-Pub 2026. PMID: 41791883.
- Hamidi S, Subbiah V, Cabanillas ME, Sherman SI, Vodopivec DM, Dadu R, Hu MI. Acquired Driver Fusions as a Mechanism of Resistance to Selective RET Inhibitors in Advanced Medullary Thyroid Carcinoma. JCO Precis Oncol 10:e2400900, 2026. e-Pub 2026. PMID: 41719512.
- Salim HA, Msherghi A, Learned K, Zafereo M, Wang J, Dagher SA, Altintas Taslicay C, Dagher R, Alizada S, Hu MI, Cabanillas ME, Busaidy N, Hamidi S, Tawbi H, Li J, Ucisik FE, Wintermark M. Prognostic Factors in Thyroid Cancer Patients With Brain Metastases: A Systematic Review and Meta-Analysis. Thyroid 35(12):1378-1390, 2025. e-Pub 2025. PMID: 40956665.
- Fournier I, Bandi AV, Hamidi S, Iyer P, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Waguespack SG, Basmaci UN, Williams MD, Mansour M, Monroe MG, Gross ND, Goepfert RP, Perrier ND, Banuchi V, Wang JR, Maniakas A, Zafereo ME. Management of Retropharyngeal Lymph Node Metastases in Thyroid Cancer. Head and Neck 48(1):237-245, 2025. e-Pub 2025. PMID: 40891104.
- Hawes EE, Banuchi VE, Maniakas A, Wang JR, Graham PH, Diersing JD, Busaidy NL, Cabanillas ME, Dadu R, Hamidi S, Iyer P, Waguespack SG, Ahmed S, Alizada S, Belcastro A, Alsharif R, Hu MI, Zafereo ME. Partial Laryngectomy for Thyroid Cancer: A Single Institution Case Series With Operative Techniques. Head Neck 48(2):E20-E24, 2025. e-Pub 2025. PMID: 40747656.
- Cabanillas, ME, Busaidy, NL, Gunn, GB, Iyer, PC, Ferrarotto, R, Gule-Monroe, MK, Maniakas, A, Williams, MD, Liu, S, Fellman, B, Spiotto, MT, Hamidi, S, Akhave, NS, Lee, A, Wang, RJ, De Sousa, LG, Marczyk, VR, Zafereo, M, Dadu, R. Adjuvant Pembrolizumab after Upfront Multimodal Therapy for Stage IVB Anaplastic Thyroid Cancer. Thyroid 35(7):763-770, 2025. e-Pub 2025. PMID: 40609521.
- Hamidi S, Zafereo ME, Wang JR, Maniakas A, Busaidy NL, Dadu R, Iyer PC, Cabanillas ME. Circulating Tumor DNA as a Biomarker for Disease surveillance in Anaplastic Thyroid Cancer. JCO Precis Oncol 9(e2500067), 2025. e-Pub 2025. PMID: 40570261.
- Hamidi S, Maniakas A, Akhave NS, Banuchi VE, Busaidy NL, Dadu R, Ferrarotto R, Guise TA, Hofmann M, Hosseini S, Hu MI, Iyer PC, Mansour M, Marczyk VR, Roy-Chowdhuri S, Sherman SI, Sousa LG, Wang JR, Williams MD, Zafereo ME, Waguespack SG, Cabanillas ME. Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues. The Journal of Clinical Endocrinology & Metabolism 111(2):471-483, 2025. e-Pub 2025. PMID: 40568752.
- Cabanillas, ME, Akhave, NS, Banuchi, VE, Busaidy, NL, Dadu, R, Ferrarotto, R, Gunn, GB, Hamidi, S, Hofmann, M, Hosseini, SM, Iyer, PC, Lai, SY, Lee, A, Maniakas, A, Ning, M, Spiotto, MT, Wang, RJ, Williams, MD, Zafereo, M. Reimagining the Therapeutic Approach for Anaplastic Thyroid Cancer. Thyroid 35(5):462-470, 2025. e-Pub 2025. PMID: 40388579.
- Marczyk, VR, Fazeli, S, Dadu, R, Busaidy, NL, Iyer, PC, Hu, MI, Sherman, SI, Hamidi, S, Hosseini, SM, Williams, MD, Ahmed, S, Routbort, MJ, Luthra, R, Roy Chowdhuri, S, San Lucas, FA, Patel, KP, Hong, DS, Zafereo, M, Wang, RJ, Maniakas, A, Waguespack, SG, Cabanillas, ME. NTRK Fusion-Positive Thyroid Carcinoma. JCO Precision Oncology 9, 2025. e-Pub 2025. PMID: 39983078.
- Hamidi S, Ning MS, Phan J, Zafereo ME, Gule-Monroe MK, Dadu R. Recurrent Poorly Differentiated Thyroid Cancer Successfully Treated With Radiation and Immunotherapy. JCEM Case Rep 3(2), 2025. e-Pub 2025. PMID: 39866918.
- Dudzinski, SO, Cabanillas, ME, Hamidi, S, Marczyk, VR, Busaidy, NL, Dadu, R, Welsh, J, Hu, MI, Gunn, GB, Wang, C, Waguespack, SG, Phan, J, Beckham, TH, Chang, JY, Sherman, SI, Reddy, JP, Ying, AK, O'Reilly, M, Chen, A, Lee, A, Gandhi, S, Liao, Z, Ludmir, EB, Nguyen, Q, Lin, SH, Zafereo, M, Ning, M. Definitive Radiotherapy for Oligometastatic and Oligoprogressive Thyroid Cancer. JNCCN Journal of the National Comprehensive Cancer Network 23(1), 2025. e-Pub 2025. PMID: 39662038.
- Hamidi, S, Yedururi, S, Hu, MI, Busaidy, NL, Sherman, SI, Jimenez, C, Grubbs, EG, Maniakas, A, Zafereo, M, Subbiah, V, Waguespack, SG. Efficacy and Safety of Selective RET Inhibitors in Patients with Advanced Hereditary Medullary Thyroid Carcinoma. Thyroid 35(1):6-17, 2025. e-Pub 2025. PMID: 39630530.
- Hamidi S, Mahvash A, Hu MI. Paraneoplastic Diarrhea From Medullary Thyroid Carcinoma Resolved With Yttrium-90 Radioembolization of Liver Metastases. JCEM Case Rep 2(8), 2024. e-Pub 2024. PMID: 39076377.
- Hamidi S, Iyer PC, Dadu R, Gule-Monroe MK, Maniakas A, Zafereo ME, Wang JR, Busaidy NL, Cabanillas ME. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAFV600E-Mutated Anaplastic Thyroid Carcinoma. Thyroid 34(3):336-346, 2024. e-Pub 2024. PMID: 38226606.
- Hamidi S, Boucher A, Lemieux B, Rondeau G, Lebœuf R, Ste-Marie L, Le XK, Mircescu H. Lenvatinib Therapy for Advanced Thyroid Cancer: Real-Life Data on Safety, Efficacy, and Some Rare Side Effects. J Endocr Soc 6(6), 2022. e-Pub 2022. PMID: 35475024.
- Hamidi S, Mottard S, Berthiaume MJ, Doyon J, Bégin MJ, Bondaz L. Brown tumor of the iliac crest initially misdiagnosed as a giant cell tumor of the bone. Endocrinol Diabetes Metab Case Rep, 2020. e-Pub 2020. PMID: 32478667.
Invited Articles
- Li S, Wu C, Marczyk VR, Loberg MA, Thennavan A, Tarabichi M, Xu L, Henderson YC, Martin ME, Tran TM, Duose DY, Sanchez-Espitia A, Luthra R, Sheng Q, Xu GJ, Huang EC, Hofmann M, Zhao X, Lai SY, Hosseini S, Williams MD, Wang W, Hamidi S, Zafereo ME, Cabanillas ME, Navin NE, Weiss VL, Wang JR. PRECISE: A prognostic thyrocyte-derived gene signature for papillary thyroid carcinoma. Clinical Cancer Research, 2026. PMID: 42008746.
- Shariq OA, Waguespack SG, Hamidi S, Kensing BC, Hu MI, Skefos CM, Perrier ND. Approach to the Patient: Hereditary Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 110(9):2685-2697, 2025. e-Pub 2025. PMID: 40105880.
- Hamidi S, Maniakas A. Recent advances in anaplastic thyroid cancer management. Curr Opin Endocrinol Diabetes Obes 30(5):259-264, 2023. e-Pub 2023. PMID: 37410453.
Review Articles
- Hamidi, S, Maniakas, A, Cabanillas, ME. Advances in Anaplastic Thyroid Cancer Treatment. Endocrinology and Metabolism Clinics of North America 54(3):361-375, 2025. e-Pub 2025. PMID: 40716892.
- Hamidi S, Turner N, Ouni R, Rico R, Henderson YC, Puche M, Alekseev S, Colunga-Minutti JG, Zafereo ME, Lai SY, Kim ST, Cabanillas ME, Nurieva R. Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy. Front Immunol 15, 2024. e-Pub 2024. PMID: 38868771.
- Hamidi S, Hu MI. RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions. Ann Endocrinol (Paris) 85(2):118-126, 2024. e-Pub 2024. PMID: 38342224.
- Keam, S, Turner, N, Grande Kugeratski, F, Rico, R, Colunga-Minutti, JG, Poojary, R, Alekseev, S, Patel, A, Li, YJ, Sheshadri, A, Loghin, ME, Woodman, K, Aaroe, AE, Hamidi, S, Iyer, PC, Palaskas, NL, Wang, Y, Nurieva, R. Toxicity in the era of immune checkpoint inhibitor therapy. Frontiers in immunology 15, 2024. e-Pub 2024. PMID: 39247203.
- Hamidi S, Hofmann M, Iyer PC, Cabanillas ME, Hu MI, Busaidy NL, Dadu R. Review article: new treatments for advanced differentiated thyroid cancers and potential mechanisms of drug resistance. Front Endocrinol (Lausanne) 14, 2023. e-Pub 2023. PMID: 37435488.
Other Articles
- Hamidi S, Dadu R, Zafereo ME, Ferrarotto R, Wang JR, Maniakas A, Gunn G, Lee A, Spiotto MT, Iyer PC, Sousa LG, Akhave NS, Ahmed S, Learned KO, Lu C, Lai SY, Williams M, Hosseini S, Busaidy NL, Cabanillas ME Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement. JAMA Oncol, 2024. PMID: 38990526.
Letters to the Editor
- Matrone A, Kroiss M, Gild ML, Hamidi S, Sayehli CM, Siddal R, Gambale C, Prete A, Hu MI, Robinson BG, Elisei R. Erectile Dysfunction in Patients Treated with Selpercatinib for RET-Altered Thyroid Cancer. Thyroid, 2024.
Patient Reviews
CV information above last modified September 08, 2026